Month: October 2022

Davies, David L.; Fawcett, John; Garratt, Shaun A.; Russell, David R. published an article in 2004, the title of the article was Cp*Rh complexes with pyridyloxazolines: synthesis, fluxionality and applications as asymmetric catalysts for Diels-Alder reactions.Product Details of 109660-12-0 And the article contains the following content:

Half-sandwich complexes [RhCl(pymox)Cp*][SbF6] (1-7) (pymox = pyridyloxazoline) were synthesized as single diastereomers. Treatment of these with AgSbF6 generates dications [Rh(OH2)(pymox)Cp*]2+ which are fluxional at room temperature and which are enantioselective catalysts for the Diels-Alder reaction of methacrolein and cyclopentadiene. Treatment of the dication [Rh(OH2)(iPr-pymox)Cp*]2+ with [X]- gives [RhX(iPr-pymox)Cp*][SbF6] (X = Br, I) as single diastereomers while reaction with 4-Mepy (4-methylpyridine) gives [Rh(4-Mepy)(iPr-pymox)Cp*][SbF6] as a mixture of diastereomers. Two complexes, [RhCl(iPr-pymox)Cp*][SbF6] (3) and [RhCl(Bz-pymox)Cp*][SbF6] (6) were characterized by x-ray crystallog. The experimental process involved the reaction of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine(cas: 109660-12-0).Product Details of 109660-12-0

The Article related to pyridyloxazoline cyclopentadienyl rhodium chloride preparation hydrolysis ligand substitution, crystal structure cyclopentadienyl pyridyloxazoline rhodium chloride, mol structure cyclopentadienyl pyridyloxazoline rhodium chloride, methacrolein diels alder reaction cyclopentadiene catalyst pyridyloxazoline rhodium chloride and other aspects.Product Details of 109660-12-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Sutton, Cara E.; Harding, Lindsay P.; Hardie, Michaele; Riis-Johannessen, Thomas; Rice, Craig R. published an article in 2012, the title of the article was Allosteric Effects in a Ditopic Ligand Containing Bipyridine and Tetra-aza-crown Donor Units.Quality Control of [2,2′-Bipyridine]-3,3′-diamine And the article contains the following content:

The authors report the synthesis and coordination properties of a macrocyclic ligand containing bipyridine and tetraazacrown N-donor units. Both sites complex Cu(II), but the donor mode of tetraazacrown unit is controlled by the binding state of the bipyridine unit. An allosteric effect, characterized by neg. cooperative binding of a second Cu(II), is assigned to the tetraazacrown being able to coordinate through only three of its N-donors when the bipyridine site is occupied. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Quality Control of [2,2′-Bipyridine]-3,3′-diamine

The Article related to preparation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, solution speciation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, allosterism copper complexation macrocyclic bipyridine tetraazacrown ligand, crystal structure copper chloro macrocyclic bipyridine tetraazacrown ligand complex and other aspects.Quality Control of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Thongpaen, Jompol; Manguin, Romane; Dorcet, Vincent; Vives, Thomas; Duhayon, Carine; Mauduit, Marc; Basle, Olivier published an article in 2019, the title of the article was Visible Light Induced Rhodium(I)-Catalyzed C-H Borylation.Recommanded Product: 1349171-28-3 And the article contains the following content:

An efficient visible light induced Rh(I)-catalyzed regioselective borylation of aromatic C-H bonds is reported. The photocatalytic system is based on a single NHC-Rh(I) complex capable of both harvesting visible light and enabling the bond breaking/forming at room temperature The chelating nature of the NHC-carboxylate ligand was critical to ensure the stability of the Rh(I) complex and to provide excellent photocatalytic activities. Exptl. mechanistic studies evidenced a photooxidative ortho C-H bond addition upon irradiation with blue LEDs, leading to a cyclometalated Rh(III)-hydride intermediate. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Recommanded Product: 1349171-28-3

The Article related to rhodium imidazolylidenecarboxylate carbene complex preparation catalyst borylation arene, crystal structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, mol structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, carbon hydrogen activation kinetics borylation arylpyridine rhodium carbene catalyst and other aspects.Recommanded Product: 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Maronna, Astrid; Huebner, Olaf; Enders, Markus; Kaifer, Elisabeth; Himmel, Hans-Joerg published an article in 2013, the title of the article was Bisguanidines with Biphenyl, Binaphthyl, and Bipyridyl Cores: Proton-Sponge Properties and Coordination Chemistry.SDS of cas: 75449-26-2 And the article contains the following content:

Herein, the authors report on the synthesis, protonation, and coordination chem. of chelating guanidine ligands with biphenyl, binaphthyl, and bipyridyl backbones. The ligands are proton sponges, and this protonation was studied exptl. and by using quantum-chem. calculations Group 10 metal (Ni, Pd, and Pt) complexes with different metal/ligand ratios were synthesized. In the case of the bipyridyl systems, coordination occurs exclusively at the pyridine N atoms, as opposed to protonation. The spin-d. distribution and the magnetism were evaluated for paramagnetic NiII complexes with the aid of paramagnetic NMR spectroscopic studies in alliance with quantum-chem. calculations and magnetic (SQUID) measurements. Through direct delocalization from the singly occupied MOs (SOMOs), a significant amount of spin d. is placed on the guanidinyl groups, and spin polarization also transports spin d. onto the aromatic backbone. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).SDS of cas: 75449-26-2

The Article related to bisguanidine biphenyl binaphthyl bipyridyl backbone protonation proton sponge, crystal structure protonated biaryl bisguanidine group 10 metal complex, dft optimized geometry protonated biaryl bisguanidine, fluorescence bipyridyl bisguanidine, heck catalyst palladium bipyridyl bisguanidine allyl complex, spin density nickel biaryl bisguanidine and other aspects.SDS of cas: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 8, 2015, Stoessel, Philipp; Joosten, Dominik; Koenen, Nils published a patent.Reference of 6-(tert-Butyl)pyridin-3-amine The title of the patent was Polycyclic nitrogen heterocyclic compounds as semiconducting materials for components of organic electronic devices. And the patent contained the following:

Polycyclic nitrogen heterocycles I (1, X = methyne, N; E = bivalent group, forming 5- or 6-membered condensed ring; Y = O, S, 1,2-ethenediyl, imino, borylene, silylene CO, alkenylidene, SO, SO2, 1,2-ethanediyl, phosphinidene, phosphinylidene; R = H, D, halo, amino, CN, NO2, OH, CO2H, carbamoyl, silyl, boryl, acyl, phosphinyl, sulfinyl, sulfonyl, sulfo, C1-20 alkyl, alkoxy, alkylthio, alkenyl, alkynyl; R1 = R or R1-R1 = bond) and their cyclometalated platinum and iridium complexes [M(L)n(L1)m] (2, M = Ir, Pd, Pt, Os, Re; L1 = auxiliary ligand), useful as organic semiconducting materials for manufacturing of charge-transporting and charge-injecting layers in organic semiconductor devices, preferably, in organic light-emitting devices (OLEDs) and featuring glass transition temperature at least 110°, were prepared by heterocyclization of aromatic aldehydes with aromatic amines and alkenes with optional subsequent cyclometalation and complexation with protonated ligands HpL1. In an example, Povarov reaction of 500 mmol of aniline with 550 mmol of benzaldehyde and 1 mol of norbornene in 1300 mL of CH2Cl2 catalyzed with 100 mmol of BF3·OEt2 for 40 h at reflux with subsequent oxidation by 5 mol of MnO2 for 16 h at reflux in 1000 mL of 1,2-dichlorobenzene under water separation gave the invented compound (1a, shown as I, E = CH:CHCH:CH, X = CH, Y = CH2, R = R1 = H) with 56% yield. The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Reference of 6-(tert-Butyl)pyridin-3-amine

The Article related to nitrogen heterocyclic compound preparation povarov cyclization cycloalkene aldehyde amine, heterocyclic polycyclic aromatic nitrogen preparation component organic electronic device, organic semiconductor nitrogen heterocycle host hole electron transporter, metallacyclic complex iridium platinum nitrogen heterocycle preparation electroluminescence and other aspects.Reference of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Ding, Tao; Wang, Xiao-Xian; Zhang, Meng; Ou, Si-Meng; Hu, Tian-Ju published an article in 2017, the title of the article was Four new coordination polymers based on a pyridinetetracarboxylate ligand: syntheses, structures and high CO2/CH4 separation.Safety of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid And the article contains the following content:

Four new coordination polymers, [Zn(TPTA)0.5(BIBP)] (1), [Mn(TPTA)0.5(BIBP)0.5(DMF)] (2), [Zn1.5(TPTA)]·DMF·H2O (3), and [Cd1.5(TPTA)]·DMF·2H2O (4) (H4TPTA = 5,5′-(pyridine-2,5-diyl)diisophthalic acid, BIBP = 4,4′-bis(imidazol-1-yl)biphenyl), have been synthesized under solvothermal conditions and fully characterized. Single-crystal X-ray diffraction anal. revealed that complex 1 is a three-dimensional (3D) 3-fold interpenetrating architecture with (4·64·8)2(42·62·82) topol. Complex 2 possesses a 3D 2-fold interpenetrating framework based on binuclear Mn2 units with (412·63) topol. Both complexes 3 and 4 exhibit trinuclear 3D non-interpenetrating (4,8)-connected networks with (46)2(412·612·84) topol. The fluorescence properties of 1, 3 and 4 have been also measured. Importantly, gas adsorption studies for 1-4 show highly selective adsorption of CO2 over CH4. The experimental process involved the reaction of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid(cas: 1431292-15-7).Safety of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid

The Article related to zinc manganese cadmium pyridineisophthalate imidazolebiphenyl complex preparation thermal stability, crystal structure zinc manganese cadmium pyridineisophthalate imidazolebiphenyl complex, photoluminescence zinc manganese cadmium pyridineisophthalate imidazolebiphenyl complex, gas adsorption zinc manganese cadmium pyridineisophthalate imidazolebiphenyl complex and other aspects.Safety of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 14, 2003, Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes published a patent.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine The title of the patent was Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders. And the patent contained the following:

This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer’s disease. Three examples of pharmaceutical compositions containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μM for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preparations of I and many example preparations of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR’R”, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R’ is H, lower alkyl or C3-C6-cycloalkyl; R” is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH2)n-C(O)-OR”, -(CH2)n-C(O)-NR’R”, -(CH2)n-SO2-NR’R”, -(CH2)n-C(NH2):NR”, hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR’R”, hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4. The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

The Article related to alzheimer disease, anti-alzheimer agents, antipsychotics, biological memory retention defect, cognition enhancers, cognitive disorders, drug delivery systems, homo sapiens, human, metabotropic glutamate receptors role: bsu (biological study, unclassified), biol (biological study) (antagonists), nervous system agents, nervous system disease, psychosis, schizophrenia and other aspects.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 15, 2007, Wang, Jian; Djukic, Brandon; Cao, Jingyi; Alberola, Antonio; Razavi, Fereidoon S.; Pilkington, Melanie published an article.HPLC of Formula: 75449-26-2 The title of the article was A novel bis tridentate bipyridine carboxamide ligand and its complexation to copper(II): synthesis, structure, and magnetism. And the article contained the following:

A new bis tridentate ligand 2,2′-bipyridine-3,3′-[2-pyridinecarboxamide] H2L1 which can bind transition metal ions was synthesized via the condensation of 3,3′-diamino-2,2′-bipyridine together with 2-pyridine carbonyl chloride. Two Cu(II) coordination compounds were prepared and characterized: [Cu2(L1)(hfac)2].3MeCN.H2O (1) and [Cu2(L1)Cl2].MeCN (2). The single-crystal x-ray structures reveal that complex 1 crystallizes in the triclinic space group P1̅, with a 12.7185(6), b 17.3792(9), c 19.4696(8) Å, α 110.827(2), β 99.890(3), γ 97.966(3)°, Z = 4, R = 0.0321 and Rw = 0.0826. Complex 2 crystallizes in the monoclinic space group P21/n with a 12.8622(12), b 9.6100(10), c 19.897(2) Å, β 102.027(3)°, Z = 4, R = 0.0409 and Rw = 0.1005. In both complexes the ligand is in the dianionic form and coordinates the divalent CuII ions via one amido and two pyridine N donor atoms. In 1, the coordination geometry around both CuII ions is best described as distorted trigonal bipyramidal where the remaining two coordination sites are satisfied by hexafluoroacetylacetonate counterions. In 2 both CuII ions adopt a (4 + 1) distorted square pyramidal geometry. One Cu forms a longer apical bond to an adjacent carbonyl O atom, whereas the second Cu is chelated to a neighboring Cu-Cl chloride ion to afford a μ-Cl-bridged dimerized [Cu2(L1)Cl2]2 complex. The magnetic susceptibility data for 1 (2 -270 K), reveal the occurrence of weak antiferromagnetic interactions between the CuII ions. In contrast, variable-temperature magnetic susceptibility measurements for 2 reveal more complex magnetic properties, with the presence of a weak antiferromagnetic exchange (J = -10.1 K) between the Cu ions in each dinuclear Cu complex and a stronger ferromagnetic exchange interaction (J = 32.9 K) between the CuII ions of the Cu(μ-Cl)2Cu dimeric bridging units. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).HPLC of Formula: 75449-26-2

The Article related to copper bipyridinepyridinecarboxamide preparation structure magnetic exchange, crystal structure copper bipyridinepyridinecarboxamide fluoroacac chloro dinuclear, exchange ferromagnetic antiferromagnetic copper bipyridinepyridinecarboxamide and other aspects.HPLC of Formula: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2005, Kelly, Michael G.; Janagani, Satyanarayana; Wu, Guoxian; Kincaid, John; Lonergan, David; Fang, Yunfeng; Wei, Zhi-Liang published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of bicycloheteroarylamines like 2,6-naphthyridinamines and pyrido[3,4-d]pyrimidinamine as ion channel ligands and uses thereof. And the patent contained the following:

Amine compounds (shown as I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; and stereoisomers and tautomers thereof; variables defined below; e.g. 7-(3-chloropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine (shown as II)) that are VR1 (VR = vanilloid receptor) antagonists are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of nonlimiting example, pain, inflammation, traumatic injury, and others. Compounds I are considered to be particularly beneficial as VR1 antagonists as certain compounds exhibit improved aqueous solubility and metabolic stability. For I: A and B = CH2, CR2’R2′, CO, CS and NR2′; Y = CH2, CR2’R2′ and NR2′; W and Z = CR4 and N, provided that W and Z both can not be N; R1 = (un)substituted aliphatic, alkyl, heteroalkyl, acyl, aryl, heteroaryl, aralkyl, heteroalkyl; each of R2 and R2′ = H, or (un)substituted C1-C6 alkyl, C1-C6 cycloalkyl, aryl and aralkyl; R3 = (un)substituted C1-C6 alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, bicycloalkyl, bicycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, and bicycloheteroaryl ring. R4 = H, or (un)substituted alkyl, (un)substituted acyl, (un)substituted acylamino, (un)substituted alkylamino, (un)substituted alkylthio, (un)substituted alkoxy, (un)substituted alkoxycarbonyl, (un)substituted alkylarylamino, (un)substituted arylalkyloxy, amino, (un)substituted aryl, arylalkyl, (un)substituted sulfoxide, (un)substituted sulfone, (un)substituted mercapto, (un)substituted aminosulfonyl, (un)substituted arylsulfonyl, sulfuric acid, sulfuric acid ester, (un)substituted dihydroxyphosphoryl, (un)substituted aminodihydroxyphosphoryl, azido, carboxy, (un)substituted carbamoyl, carboxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted dialkylamino, halo, heteroaryloxy, (un)substituted heteroaryl, (un)substituted heteroalkyl, hydroxy, nitro, and thio. Although the methods of preparation are not claimed, 62 example preparations are included. For example, II was prepared in 5 steps (90, 38, 91, 87, 26 % yields) starting from 1-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride, formamidine acetate and NaOMe/MeOH and involving intermediates 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 7-benzyl-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine, and N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine. VR1 antagonist activity for 62 examples of I, capsaicin-induced VR1 current inhibition activity for 16 examples of I, reversal of thermal hyperalgesia in rats by II, pharmacokinetic profiles for 5 examples of I and plasma protein binding ability by II are reported. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to naphthyridinamine pyridopyrimidinamine preparation vanilloid receptor antagonist, ion channel ligand naphthyridinamine pyridopyrimidinamine preparation, pain inflammation traumatic injury drug naphthyridinamine pyridopyrimidinamine preparation and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem